1. Scrip
  2. >>Drug Pricing

Mylan's Generic EpiPen: A Good PR Move, But Risks Alienating Payers

 
• By Donna Young

Mylan's plan to provide a generic version of its emergency allergic reaction drug EpiPen may be a good PR move, but it may alienate payers further. It also has spurred new skepticism about the company's pricing practices.

Mylan NV's plan to launch its own generic version of its emergency allergic reaction drug EpiPen (epinephrine) wasn't enough to stave off the critics over the branded product's $608 list price or blunt the moxie of a compounder looking to bring a much lower cost alternative to patients.

Mylan's move would, nonetheless, potentially keep the company somewhat ahead of any potential rivals aiming to take a bite out...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

Medicare Price Cuts For 15 Drugs In 2027 Likely Not As Large As CMS Estimates

 
• By Mandy Jackson

Under the Inflation Reduction Act, CMS negotiated lower Medicare Part D prices for 15 drugs with 2027 costs 38%-85% lower than 2024 list prices, but analyses of net prices paid last year show smaller discounts.

Medicare Negotiations 2.0 Slash Prices Up To 85%, But Mean Cuts Barely Budge

 
• By Manas Mishra

The second cycle of IRA price negotiations could result in price cuts as high as 85% to the 2024 list prices, but the mean discount across the 15 negotiated drugs appears similar to the previous round.

Itvisma Broad Label A Big Boon For Novartis’s SMA Revenues

 
• By Kevin Grogan

US FDA approval of the intrathecal formulation of Zolgensma means many more patients with spinal muscular atrophy will be eligible for the gene therapy.

Arrowhead’s Redemplo Approval Sets Up Standoff With Ionis’s Tryngolza

 
• By Jessica Merrill

Redemplo is Arrowhead’s first commercial product, and the drug will enter a competitive market. Arrowhead and Ionis have taken different pricing paths, however.

More from Scrip

Pipeline Watch: Eight Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Sibeprenlimab’s US Accelerated Approval Drives IgAN Competition Forward

 
• By Lisa Takagi

Following US approval of its first-in-class drug for IgAN sibeprelimab, Otsuka is planning an sNDA for an autoinjector in 2026 and is in talks with regulatory authorities in Japan and Europe.

The Rise of China Biopharma – Five Themes In 2025

 
• By Andrew McConaghie

The growth of China’s biopharma sector has been perhaps the most significant sector trend this year – Scrip outlines five themes that have emerged during 2025 and in discussions at the recent Jefferies conference in London.